Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43509 | 0.88 | CYP3A4 (1.00) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL30097830 | 0.88 | CYP3A4 (1.00) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL12107538 | 0.88 | CYP3A4 (0.54) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL8765734 | 0.86 | CYP3A4 (0.95) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| Ammonia Solution, Strong SCHEMBL9140534 | 0.86 | CYP3A4 (0.95) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL12706760 | 0.82 | CYP3A4 (0.48) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL11058899 | 0.82 | CYP3A4 (0.87) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| Toluene SCHEMBL9700648 | 0.81 | CYP3A4 (0.71) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL25128158 | 0.80 | CYP3A4 (0.69) | CYP3A4ALDH1A1GAAKDM4EMAPT | |
| SCHEMBL5271470 | 0.80 | CYP3A4 (0.83) | CYP3A4ALDH1A1GAAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9511320-B2 | Polyimide-based macromolecular compound and gas-separation asymmetrical hollow-fibre membrane comprising the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2016-12-06 | — | — | US | disclosed |
| US-20150217225-A1 | POLYMIDE-BASED MACROMOLECULAR COMPOUND AND GAS-SEPARATION ASYMMETRICAL HOLLOW-FIBRE MEMBRANE COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2015-08-06 | — | — | US | disclosed |
| US-8765781-B2 | Bis-carbazole DNA intercalating agents for antitumor therapy | TRUSTEES OF DARTMOUTH COLLEGE (US) | 2014-07-01 | — | — | US | disclosed |
| US-20110118296-A1 | Bis-Carbazole DNA Intercalating Agents for Antitumor Therapy | TRUSTEES OF DARTMOUTH COLLEGE | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118296-A1 | Bis-Carbazole DNA Intercalating Agents for Antitumor Therapy | TOP1, TOP2A, TOP2B | CYP3A4 2329/4885ALDH1A1 2612/4885GAA 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.